SCHEMBL3636951

SCHEMBL3636951

Oc1ccc(CNc2nc(NCc3ccc(F)cc3)nc3ccccc23)cc1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.69
LMNA P02545 2/20 0.68
MAPT P10636 2/20 0.68
KMT2A Q03164 2/20 0.68
KDM4E B2RXH2 1/20 0.68
ALDH1A1 P00352 1/20 0.68
PKM P14618 1/20 0.68
UBE2N P61088 1/20 0.68
NPSR1 Q6W5P4 1/20 0.68
RCE1 Q9Y256 1/20 0.68
APP P05067 3/20 0.66
MEN1 O00255 1/20 0.66
CTNNB1 P35222 5/20 0.62
TCF7L2 Q9NQB0 5/20 0.62
BCHE P06276 3/20 0.61
ACHE P22303 3/20 0.61
NTRK1 P04629 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2590855 0.92 RAD52 (0.82) RAD52LMNAMAPTKMT2AKDM4E
Hydrochloric Acid SCHEMBL3643618 0.91 MAPT (0.83) RAD52LMNAMAPTKMT2AKDM4E
SCHEMBL3642835 0.86 RAD52 (0.72) RAD52LMNAMAPTKMT2AKDM4E
SCHEMBL12175837 0.83 RAD52 (1.00) RAD52LMNAMAPTKMT2AKDM4E
SCHEMBL21567246 0.82 BCHE (0.83) RAD52LMNAMAPTKMT2AKDM4E
SCHEMBL29490089 0.82 CTNNB1 (0.77) RAD52LMNAMAPTKMT2AKDM4E
SCHEMBL22342962 0.82 CTNNB1 (0.77) RAD52LMNAMAPTKMT2AKDM4E
SCHEMBL2580376 0.80 RAD52 (0.76) RAD52LMNAMAPTKMT2AKDM4E
SCHEMBL3769816 0.80 CTNNB1 (0.65) RAD52LMNAMAPTKMT2AKDM4E
SCHEMBL2583554 0.80 MEN1 (1.00) LMNAMAPTKMT2AALDH1A1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317607-A1 USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS INFECTIOUS DISEASE RESEARCH INSTITUTE (US) 2010-12-16 US claimed
EP-2173346-A2 USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS Summit Corporation Plc (GB) 2010-04-14 EP claimed
WO-2009001060-A2 USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS SUMMIT CORPORATION PLC (GB) 2008-12-31 WO claimed
US-20100317607-A1 USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS INFECTIOUS DISEASE RESEARCH INSTITUTE (US) 2010-12-16 US disclosed
EP-2173346-A2 USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS Summit Corporation Plc (GB) 2010-04-14 EP disclosed
WO-2009001060-A2 USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS SUMMIT CORPORATION PLC (GB) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317607-A1 USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS TPX2, DCXR, RRM2 RAD52 1076/4885LMNA 1934/4885MAPT 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.